Payment overview · 2025
General Payments
$899.00
48 reported records · 12 companies
Healthcare provider profile · identity verified
Charles Kent, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · TALLAHASSEE, FL · NPI 1205891850
Verified facts
What the public records show
CMS Open Payments records show Charles Kent, M.D. received $899.00 in general payments during 2025 across 48 reported records.
ABBVIE INC. accounted for 40.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $366.07 | 40.7% | 21 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $177.67 | 19.8% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $59.08 | 6.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.92 | 5.7% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $49.71 | 5.5% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $46.30 | 5.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $39.85 | 4.4% | 2 | 2025 |
| Theratechnologies Inc. | Unresolved — no canonical attribution shown | $29.86 | 3.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.74 | 2.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.90 | 2.5% | 1 | 2025 |
| Ferring Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.21 | 2.0% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $14.69 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $899.00 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $275.04 | 15 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $91.03 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $85.33 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $59.08 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $51.91 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $49.71 | 2 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $46.30 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $39.85 | 2 | 2025 |
Source payment records
|
|||||
| EGRIFTA Normalized: egrifta |
Drug | Theratechnologies Inc. | $29.86 | 1 | 2025 |
Source payment records
|
|||||
| TROGARZO Normalized: trogarzo |
Drug | Theratechnologies Inc. | $29.86 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.22 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $25.01 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.74 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.90 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.90 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| EUFLEXXA Normalized: euflexxa |
Device | Ferring Pharmaceuticals Inc. | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.40 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 108 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
108 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 265 | 73 |
| Atorvastatin Calcium | Atorvastatin Calcium | 244 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 236 | 64 |
| Lisinopril | Lisinopril | 235 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 210 | 61 |
| Metformin Hcl | Metformin Hcl | 193 | 50 |
| Losartan Potassium | Losartan Potassium | 162 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 139 | 36 |
| Omeprazole | Omeprazole | 117 | 31 |
| Farxiga | Dapagliflozin Propanediol | 108 | 22 |
| Tramadol Hcl | Tramadol Hcl | 108 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 93 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 24 |
| Gabapentin | Gabapentin | 80 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 79 | 20 |
| Furosemide | Furosemide | 75 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 74 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 20 |
| Simvastatin | Simvastatin | 73 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 72 | 25 |
| Famotidine | Famotidine | 71 | 19 |
| Irbesartan | Irbesartan | 71 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 66 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | suppressed |
| Alprazolam | Alprazolam | 61 | 14 |
| Prednisone | Prednisone | 61 | 50 |
| Sertraline Hcl | Sertraline Hcl | 61 | 15 |
| Montelukast Sodium | Montelukast Sodium | 53 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | 14 |
| Lorazepam | Lorazepam | 44 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 15 |
| Trulicity | Dulaglutide | 43 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 15 |
| Ozempic | Semaglutide | 42 | suppressed |
| Memantine Hcl | Memantine Hcl | 40 | 13 |
| Trazodone Hcl | Trazodone Hcl | 40 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 39 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | 11 |
| Valsartan | Valsartan | 37 | suppressed |
| Allopurinol | Allopurinol | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Carvedilol | Carvedilol | 31 | suppressed |
| Glimepiride | Glimepiride | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Meloxicam | Meloxicam | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | suppressed |
| Eliquis | Apixaban | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Potassium Chloride | Potassium Chloride | 18 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Fluocinonide | Fluocinonide | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 11 | suppressed |
| Bystolic | Nebivolol Hcl | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $899.00 · 48 records | ABBVIE INC. | AIRSUPRA, AREXVY, BREZTRI, Bimzelx, EGRIFTA, ELIQUIS, EUFLEXXA, FARXIGA, FREESTYLE LIBRE 3, Flexitouch Plus, Kerendia, NURTEC ODT, Nimbl, Ozempic, QULIPTA, Rybelsus, TRELEGY ELLIPTA, TROGARZO, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error